MAPT and myeloid sarcoma: Moreover, in comparison with control patients, total tau concentration significantly differed only from MS patients with ≥9 lesions (68.77 pg/mL, IQR 31.24–109.17, and 168.33 pg/mL, IQR 111.67–222.32, p = 0.003; Figure 2a).